MP13-14 USE OF NEOADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: A POPULATION-BASED STUDY, 2006-2017

Abstract

You have accessJournal of UrologyBladder Cancer: Invasive I (MP13)1 Sep 2021MP13-14 USE OF NEOADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: A POPULATION-BASED STUDY, 2006-2017 Natasza Posielski, Nathan Jung, Hannah Koenig, On Ho, John Paul Flores, and Christopher Porter Natasza PosielskiNatasza Posielski More articles by this author , Nathan JungNathan Jung More articles by this author , Hannah KoenigHannah Koenig More articles by this author , On HoOn Ho More articles by this author , John Paul FloresJohn Paul Flores More articles by this author , and Christopher PorterChristopher Porter More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001994.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Current guidelines recommend neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) for muscle invasive bladder cancer (MIBC). NAC has been shown to confer a survival benefit across all ages. Yet, many elderly patients are not offered NAC due to concern regarding physiologic reserve and postoperative complications. Our objective was to evaluate age-based disparity in treatment and outcomes of MIBC. METHODS: Using the National Cancer Database, we identified patients with MIBC from 2006-2017. First, use of different treatments including RC, RC and adjuvant chemotherapy, RC with NAC (“optimal treatment”), chemo-radiation, and no treatment, was compared between age groups. A second analysis was performed in the cohort of elderly patients, ≥70, undergoing cystectomy. Propensity weighting was used to compare peri-operative and mortality outcomes in those who received NAC vs. no NAC. RESULTS: In 70,911 patients with non-metastatic MIBC, use of RC with NAC was lower in patients ≥70, 7.2 vs. 20.9%, p<0.001 (Table 1, Figure 1). Patients receiving RC with NAC were younger, had private insurance, higher high school completion rate and median income, shorter distance to hospital, lower CCI, diagnosis in recent years, and higher stage disease. NAC use was also associated with pelvic lymph node dissection (OR 4.55, p<0.001). In patients ≥70 undergoing RC, NAC was associated with shorter length of stay (LOS) (8.5 vs 9.6 days, p<0.001), decreased 30-day readmission (8.6 vs 10.6%, p=0.003), lower 30- and 90-day mortality (1.9 vs 3.6%, p=0.01 and 4.9 vs 7.7%, p=0.004, respectively), and better overall survival (OS) (43.8% vs. 37.5%, p<0.001). Multivariate logistic regression found NAC as an independent predictor of shorter LOS, lower 30-and 90-day mortality, and improved OS. CONCLUSIONS: Despite increased omission of NAC in patients ≥70, NAC is not associated with worse peri-operative outcomes or mortality in elderly patients. Advanced age in properly selected patients should not preclude offering NAC prior to radical cystectomy. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e249-e249 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Natasza Posielski More articles by this author Nathan Jung More articles by this author Hannah Koenig More articles by this author On Ho More articles by this author John Paul Flores More articles by this author Christopher Porter More articles by this author Expand All Advertisement Loading ...